Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00492 (
hypoxanthine-guanine phosphoribosyltransferase
)
2,385
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ochratoxin A
(
OTA
) is a widespread mycotoxin in food and a powerful nephrocarcinogen in rats. The mutagenicity of
OTA
has been extensively investigated but with conflicting results, thus leaving open the mechanistic question for
OTA
carcinogenicity. Here, we examined the mutagenicity of
OTA
by using well-standardized mutation assays such as the
hypoxanthine-guanine phosphoribosyltransferase
(
HPRT
) assay in Chinese hamster V79 cells and the thymidine kinase assay in mouse lymphoma LY5178 cells.
OTA
-induced
HPRT
mutations were characterized at the molecular level. In V79 cells,
OTA
produced a dose- and time-related decrease in cell number as a consequence of the transitory cytostatic effect mediated by G2/M cell cycle arrest. In both mutation assays,
OTA
was weakly mutagenic and this effect was independent of biotransformation.
OTA
-induced mutations were characterized by point mutations (48%) and a lack of a detectable reverse-transcription polymerase chain reaction product (52%). The pattern of
OTA
-induced point mutations was similar to that of spontaneous mutants, suggesting that
OTA
induced an increase of the endogenous oxidative metabolism but not covalent DNA adducts. Our data support a model where
OTA
is mutagenic via oxidative DNA damage induction.
...
PMID:Ochratoxin A-induced mutagenesis in mammalian cells is consistent with the production of oxidative stress. 1756 56